INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors - read this article along with other careers information, tips and advice on BioSpace
CDC facing formidable challenges in convincing conservatives to get COVID-19 vaccines
Public health experts at the US Centers for Disease Control and Prevention are facing challenges even struggling as they try to figure out how to convince hesitant Republicans to take the COVID-19 vaccine, federal officials familiar with the situation told CNN.
“It’s kind of a mess to figure out with this particular audience what resonates with them, because they see vaccines as taking away their freedom,” said one official. “It’s a hard climb for everyone in public health. It’s moving a rock up a mountain.”
According to a Kaiser Family Foundation survey in April of more than 2,000 people in the US, 42% of Republicans, but only 19% of Democrats, are less than enthusiastic about getting the COVID-19 vaccine.
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
News provided by
Share this article
Up to 200,000 Johnson & Johnson
Ebola vaccine regimens will be made available as part of a WHO early access clinical program now underway in Sierra Leone
Company s Ebola vaccine regimen also receives Prequalification from the WHO
The Johnson & Johnson vaccine regimen is designed to be used proactively to induce immunity against Ebola in adults and children
NEW BRUNSWICK, N.J., May 13, 2021 /PRNewswire/ Johnson & Johnson (NYSE: JNJ) (the Company) today announced the World Health Organization (WHO) and the government of Sierra Leone have begun administering the Company s Ebola vaccine regimen as part of a WHO early access clinical program aimed at preventing further spread of Ebola in West Africa. The vaccine regimen, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) in collaboration with Bavarian Nordic A/S,
This figure presents serum binding and functional antibody responses following COVID-19 vaccination and SARS-CoV-2 infection among women 45 years or younger.
A and B, Each panel compares vaccine antibody responses at 2 through 8 weeks after the second dose to nonpregnant and pregnant women who were unvaccinated and infected. Thirteen women (7 nonpregnant, 4 pregnant, and 2 lactating) who had baseline samples collected within 7 days of their first vaccine dose were selected based on the earliest sample availability and were analyzed as a negative assay control.
C, D, and E, Systems serology was used to quantify spike-specific antibody–dependent neutrophil phagocytosis (ADNP), antibody–dependent complement deposition (ADCD), and antibody–dependent monocyte cellular phagocytosis (ADCP).
/PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from.